Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer : Targeted Therapy - 19/05/20
, Ah-Reum Jeong, MD, James Buturla, MD, Lyudmila Bazhenova, MDRésumé |
The treatment of metastatic non–small cell lung cancer (NSCLC) is constantly evolving. Although the advent of immunotherapy has played an important role in the treatment of patients with NSCLC, the identification of driver mutations and the subsequent specific treatment of these targets often lead to durable responses while maintaining quality of life. This review delves into targeted therapies available for epidermal growth factor receptor, anaplastic lymphoma kinase, ROS1, neurotrophic tropomyosin receptor kinase, and BRAF- mutated NSCLC patients, as well as other mutations with promising novel drugs under clinical investigation.
Le texte complet de cet article est disponible en PDF.Keywords : Lung cancer, Non–small cell lung cancer (NSCLC), Tyrosine kinase inhibitor (TKI), Targeted therapy, EGFR, ALK, ROS1, NTRK, BRAF
Plan
Vol 41 - N° 2
P. 223-235 - juin 2020 Retour au numéro
Article précédent
- Advances in the Treatment of Stage III Non–Small Cell Lung Cancer
- Nathaniel J. Myall, Millie Das
- Advances in the Treatment of Non–Small Cell Lung Cancer : Immunotherapy
- Shetal A. Patel, Jared Weiss
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?